Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Int J Mol Sci. 2020 Mar 21;21(6):2164. doi: 10.3390/ijms21062164.
Hepatocellular carcinoma (HCC) is the strongest independent predictor of mortality in non-alcoholic steatohepatitis (NASH)-related cirrhosis. The effects and mechanisms of combination of sodium-dependent glucose cotransporter inhibitor and canagliflozin (CA) and dipeptidyl peptidase-4 inhibitor and teneligliptin (TE) on non-diabetic NASH progression were examined. CA and TE suppressed choline-deficient, L-amino acid-defined diet-induced hepatic fibrogenesis and carcinogenesis. CA alone or with TE significantly decreased proinflammatory cytokine expression. CA and TE significantly attenuated hepatic lipid peroxidation. In vitro studies showed that TE alone or with CA inhibited cell proliferation and TGF-β1 and α1 (I)-procollagen mRNA expression in Ac-HSCs. CA+TE inhibited liver fibrogenesis by attenuating hepatic lipid peroxidation and inflammation and by inhibiting Ac-HSC proliferation with concomitant attenuation of hepatic lipid peroxidation. Moreover, CA+TE suppressed in vivo angiogenesis and oxidative DNA damage. CA or CA+TE inhibited HCC cells and human umbilical vein endothelial cell (HUVEC) proliferation. CA+TE suppressed vascular endothelial growth factor expression and promoted increased E-cadherin expression in HUVECs. CA+TE potentially exerts synergistic effects on hepatocarcinogenesis prevention by suppressing HCC cell proliferation and angiogenesis and concomitantly reducing oxidative stress and by inhibiting angiogenesis with attenuation of oxidative stress. CA+TE showed chemopreventive effects on NASH progression compared with single agent in non-diabetic rat model of NASH, concurrent with Ac-HSC and HCC cell proliferation, angiogenesis oxidative stress, and inflammation. Both agents are widely, safely used in clinical practice; combined treatment may represent a potential strategy against NASH.
肝细胞癌(HCC)是非酒精性脂肪性肝炎(NASH)相关肝硬化患者死亡的最强独立预测因子。本研究旨在探讨钠依赖性葡萄糖共转运蛋白抑制剂卡格列净(CA)和二肽基肽酶-4 抑制剂替格列汀(TE)联合应用对非糖尿病 NASH 进展的作用及其机制。CA 和 TE 可抑制胆碱缺乏、L-氨基酸定义饮食诱导的肝纤维化和肝癌发生。CA 单药或与 TE 联合应用可显著降低促炎细胞因子的表达。CA 和 TE 可显著减轻肝脂质过氧化。体外研究表明,TE 单药或与 CA 联合应用可抑制 Ac-HSCs 的细胞增殖和 TGF-β1 和α1(I)-前胶原 mRNA 的表达。CA+TE 通过减轻肝脂质过氧化和炎症、抑制 Ac-HSC 增殖,同时减轻肝脂质过氧化,抑制肝纤维化。此外,CA+TE 抑制体内血管生成和氧化 DNA 损伤。CA 或 CA+TE 抑制 HCC 细胞和人脐静脉内皮细胞(HUVEC)的增殖。CA+TE 抑制血管内皮生长因子的表达,并促进 HUVECs 中 E-钙黏蛋白的表达增加。CA+TE 通过抑制 HCC 细胞增殖和血管生成,同时降低氧化应激,以及通过抑制血管生成和减轻氧化应激,对 HCC 发生具有协同抑制作用。与单药治疗相比,CA+TE 在非糖尿病 NASH 大鼠模型中具有更好的 NASH 进展化学预防作用,同时伴有 Ac-HSC 和 HCC 细胞增殖、血管生成、氧化应激和炎症。两种药物在临床实践中均广泛、安全使用;联合治疗可能是针对 NASH 的一种潜在策略。